Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma

Human Pathology

Volumn 39, Issue 3, 2008, Pages 344-349

  Ch'ng, Sydney ^a,b   Low, Irene ^c   Ng, Daniel ^d   Brasch, Helen ^b   Sullivan, Michael ^e   Davis, Paul ^a   Tan, Swee T ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b HUTT HOSPITAL   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d Innovative Genetic Diagnosis ^*  (New Zealand)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Biomarker; Epidermal growth factor receptor; Squamous cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION; GENES, ERBB-1; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 38849091450     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.07.004     Document Type: Article

References (26)

1. Rudolph R., and Zelac D. Squamous cell carcinoma of the skin. Plast Reconstr Surg 114 (2004) 82e-94e
2. Australian Cancer Network Management of Non-Melanoma Skin Cancer Working Party. National Health and Medical Research Council. Clinical practice guidelines: non-melanoma skin cancer-guidelines for treatment and management in Australia (2002) 29-31
3. Ch'ng S., Maitra A., Lea R., Brasch H., and Tan S.T. Parotid metastasis-an independent prognostic factor for head and neck cutaneous squamous cell carcinoma. J Plast Reconstr Aesthet Surg 59 (2006) 1288-1293
4. Santini J., Formento J., Francoual M., et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13 (1991) 132-139
5. Dassonville O., Formento J., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11 (1993) 1873-1878
6. Xia W., Lau Y., Zhang H., et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5 (1999) 4164-4174
7. O-charoenrat P., Rhys-Evans P., Archer D., et al. C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 38 (2002) 73-80
8. Storkel S., Reichert T., Reiffen K., et al. EGFR and PCNA expression in oral squamous cell carcinomas-a valuable tool in estimating the patient's prognosis. Eur J Cancer B Oral Oncol 29B (1993) 273-277
9. Yano S., Kondo K., Yamaguchi M., et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23 (2003) 3639-3650
10. Choong N., and Cohen E. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol 57 (2006) 25-43
11. Alvarez G., Perry A., Tan B., and Wang H. Expression of epidermal growth factor amplification. Mod Pathol 19 (2006) 942-949
12. Buerger H., Gebhardt F., Schmidt H., et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenic alterations and epithelial growth factor receptor expression. Cancer Res 60 (2000) 854-857
13. Gerbhardt F., Zanker K., and Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem (1999) 13176-13180
14. Liu W., Innocenti F., Chen P., et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 9 (2003) 1009-1012
15. Liu W., Innocenti F., Wu M., et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 65 (2005) 46-53
16. Pao W., and Miller V. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 2556-2568
17. Kuan C., Wikstrand C., and Bigner D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8 (2001) 83-96
18. Grandis J., Tweardy D., and Melhem M. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 4 (1998) 13-20
19. Grandis J., and Tweardy D. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 (1993) 3579-3584
20. Karunagaran D., Tzahar E., Beerli R., et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15 (1996) 254-264
21. Worthylake R., Opresko L., and Wiley H. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274 (1999) 8865-8874
22. Cohen E., Rosen F., Stadler W., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
23. Soulieres D., Senzer N., Vokes E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
24. Trigo J., Hitt R., Koralewski P., et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. J Clin Oncol 22 (2004) [Abstract 5502]
25. Maubec E., Duvillard P., Velasco V., et al. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 25 (2005) 1205-1210
26. Glisson B., Kim E., Kies M., et al. Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin. J Clin Oncol 24 (2006) [Abstract 5531]